Opko Health (OPK) reported earnings Mon 9 Nov 2015 (after close)

** charts before earnings **

 ** charts after earnings **

 Opko Health: Co beats by $0.26, beats on revs:

• Reports Q3 (Sep) earnings of $0.25 per share, $0.26  better than the Capital IQ Consensus of ($0.01); revenues rose 622.2% year/year to $143 mln vs the $133.04 mln Capital IQ Consensus.
• Rayaldee PDUFA Date is March 29, 2016; "Our NDA filing for Rayaldee continues to advance through the FDA drug approval process and we have high expectations for our new treatment option for patients with stage 3 or 4 chronic kidney disease and secondary hyperparathyroidism."
• Completed Enrollment in Ongoing Phase 3 Trial in Growth Hormone Deficient Adults
• Cash, cash equivalents and marketable securities were $212.1 million as of September 30, 2015.